The health care giant doesn’t obtain the desired results, opts to discontinue preladenant drug trials.

The FDA advisory committee has discussed Suvorexant; now shareholders need to get ready for the agency's final decision this summer.

May 23 (Reuters) - Merck & Co has ended development of preladenant, an experimental drug for Parkinson's disease, after initial data from three late-stage trials proved disappointing.

May 23 (Reuters) - Merck & Co has ended development of preladenant, an experimental drug for Parkinson's disease, after initial data from three late-stage trials proved disappointing.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, todayprovided an update on the clinical program for preladenant, Merck'sinvestigational adenosine A2[A ]receptor antagonist for the treatment ofParkinson's disease (PD).

By Trade In Mexico:While many stocks are trading near 52-week highs or at stretched valuations, investors who selectively seek opportunities can find value in this market. For example, Merck (MRK) shares were trading at nearly $49, but a recent pullb

By Toni Clarke WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug moved a step closer to U.S. approval on Wednesday after a...

CHICAGO, May 23 (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis

CHICAGO, May 23 (Reuters) - Kathrin Jansen is amicrobiologist with at least two breakthrough vaccines to hername: she brought the cervical cancer vaccine Gardasil to marketfor Merck and helped develop the $4 billion a year pneumonia andmeningitis vac

CHICAGO, May 23 (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis

CHICAGO (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine

Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfiz

CHICAGO, May 23 (Reuters) - Kathrin Jansen is amicrobiologist with at least two breakthrough vaccines to hername: she brought the cervical cancer vaccine Gardasil to marketfor Merck and helped develop the $4 billion a year pneumonia andmeningitis vac

CHICAGO, May 23 (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis

CHICAGO, May 23 (Reuters) - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis

* FDA panel says suvorexant safe, effective at lower doses

* FDA panel says suvorexant safe, effective at lower doses

* FDA panel says suvorexant safe, effective at lower doses

Merck (NYSE: MRK), known as MSD outside the United States and Canada,today provided the following statement after the conclusion of thePeripheral and Central Nervous System Drugs Advisory Committee meetingof the U.S.

WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Adminis

WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Adminis

WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug was safe and effective at the lowerof two doses studied, a panel of medical experts said onWednesday, increasing the chance...

A federal advisory panel on Wednesday partly endorsed a proposed sleep drug from Merck, saying the product was effective and acceptably safe at lower starting doses.

WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug is safe and effective at the lower of two doses studied but not at the higher, a panel of medical experts said on Wednesday.

WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug is safe and effective at the lower oftwo doses studied but not at the higher, a panel of medicalexperts said on Wednesday.

WASHINGTON, May 22 (Reuters) - Merck & Co's experimental insomnia drug is safe and effective at the lower of two doses studied but not at the higher, a panel of medical experts said on Wednesday.

* Merck to sell Geneva site to Bertarelli-backed consortium

By The Swiss Trader:In April the global health care giant Merck & Co. (MRK), received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for its investigational antibody therapy, lambrolizumab, a drug that treats pati

(Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.

Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.

May 21 (Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.

May 21 (Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.

May 21 (Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff...

May 21 (Reuters) - Merck & Co Inc said it has entered into a $5 billion share repurchase agreement with Goldman Sachs Group Inc, as the drug giant looks to prop up shareholder value in face of stiff competition from makers of less-costly generics.

The pharmaceutical company plans to buy back $5 billion worth of its stock.

Index ends at all-time highs, driven by Fed talk and a housing comeback.

LONDON, May 21 (Reuters) - British farmers will be the first in Europe to get a vaccine against Schmallenberg virus, a new livestock disease that hit the continent in 2011.

LONDON, May 21 (Reuters) - British farmers will be the first in Europe to get a vaccine against Schmallenberg virus, a new livestock disease that hit the continent in 2011.

LONDON, May 21 (Reuters) - British farmers will be the firstin Europe to get a vaccine against Schmallenberg virus, a newlivestock disease that hit the continent in 2011.

FDA staff said a proposed sleep drug from Merck was effective, but questioned the safety of the product's higher doses. Merck is seeking FDA approval of a drug called suvorexant to treat insomnia. The product will be reviewed Wednesday by an FDA advi

Merck & Co., Inc. (MRK)UBS Global Healthcare Conference CallMay 20, 2013 10:30 a.m. ETExecutivesPeter N. Kellogg - Executive Vice President and Chief Financial OfficerAnalystsMarc Goodman - UBSPresentationMarc Goodman - UBSSo good morning everybody,

* Reviewers say lower doses of suvorexant safer than high * Cite risk of next-day sedation, suicidal thinking * Merck shares fall 1 percent in...

* Designed to help patients fall asleep, stay asleep * Merck's shares fall 1.1 percent to $45.47 By Toni Clarke May 20 (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food

* Designed to help patients fall asleep, stay asleep * Merck's shares fall 1.1 percent to $45.47 By Toni Clarke May 20 (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food

May 20 (Reuters) - *FDA STAFF REVIEWERS SAY CLINICAL TRIALS OF MERCK'S SLEEP DRUG SUVOREXANT "OVERALL, ESTABLISH EFFECTIVENESS." *FDA STAFF REVIEWERS SAY SUVOREXANT SEEMS TO BE ASSOCIATED WITH EVENTS THAT CAN BE CONSIDERED ELEMENTS OF A "NARCOLEPSY-L

ByNorthwest Trader:On December 19th, 2012 Oncothyreon's (ONTY) shares fell roughly 50% as development partner Merck KGaA (MKGAY.PK) reported that L-BLP25 (or Stimuvax), a cancer immunotherapy that was being tested against non small-cell lung cancer (

The Food and Drug Administration will decide on drugs developed by Merck, Antares Pharmaceuticals, and GlaxoSmithKline in the coming months.